↓ Skip to main content

Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers

Overview of attention for article published in Breast Cancer Research and Treatment, June 2025
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

bluesky
1 Bluesky user

Readers on

mendeley
10 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers
Published in
Breast Cancer Research and Treatment, June 2025
DOI 10.1007/s10549-025-07747-x
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Ph. D. Student 3 30%
Unspecified 1 10%
Unknown 6 60%
Readers by discipline
Readers by discipline Count As %
Unspecified 1 10%
Pharmacology, Toxicology and Pharmaceutical Science 1 10%
Immunology and Microbiology 1 10%
Engineering 1 10%
Unknown 6 60%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 June 2025.
All research outputs
#19,631,043
of 28,447,311 outputs
Outputs from Breast Cancer Research and Treatment
#4,084
of 5,458 outputs
Outputs of similar age
#81,998
of 161,575 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#14
of 19 outputs
Altmetric has tracked 28,447,311 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,458 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 161,575 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.